Results 31 to 40 of about 2,191 (125)

Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer

npj Precision Oncology
Patients treated with RET protein tyrosine kinase inhibitors (TKIs) selpercatinib or pralsetinib develop RET TKI resistance by secondary RET mutations or alterative oncogenes, of which alterative oncogenes pose a greater challenge for disease management ...
Vivek Subbiah, Mohamed A. Gouda, J. Bryan Iorgulescu, Ramona Dadu, Keyur Patel, Steven Sherman, Maria Cabanillas, Mimi Hu, Luz E. Castellanos, Behrang Amini, Funda Meric-Bernstam, Tao Shen, Jie Wu   +12 more
doaj   +1 more source

Remarkable response to low dose of selpercatinib in a patient with RET-rearranged non-small cell lung cancer

Respiratory Medicine Case Reports
Chromosomal rearrangements of the RET (rearranged during transfection) gene are detected in approximately 1–2% of non-small cell lung cancers (NSCLC) and have function as oncogenic driver genes.
Jun Sakakibara-Konishi, Hirofumi Takahashi, Kenichiro Ito, Tomoo Ikari, Yasuyuki Ikezawa, Hidenori Kitai, Megumi Furuta, Yuta Takashima, Tetsuaki Shoji, Masahide Fukudo, Satoshi Konno   +10 more
doaj   +1 more source

Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database

BMC Cancer
Background Selpercatinib, a highly selective tyrosine kinase inhibitor, has emerged as an excellent treatment option for patients with rearranged during transfection-altered cancer. However, there is limited comprehensive safety information available for
Jiancheng Qian, Shuohan Zhang, Cheng Jiang   +2 more
doaj   +1 more source

Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma

European Thyroid Journal, 2023
The endocrine secretions of carcinomas can be life-threatening. Medullary thyroid carcinoma (MTC) is a rare cancer that is often associated with cortisol secretion, leading to paraneoplastic Cushing’s syndrome.
Marine Sitbon, Porhuoy Chou, Seydou Bengaly, Brigitte Poirot, Marie Laloi-Michelin, Laure Deville, Atanas Pachev, Ahouefa Kowo-Bille, Clement Dumont, Cécile N Chougnet   +9 more
doaj   +1 more source

Comprehensive Genomic Profiling Beyond Driver Testing in Non‐Squamous Non‐Small Cell Lung Cancer With Known Drivers

Cancer Science, EarlyView.
Figure 6 Comprehensive genomic profiling identified additional actionable alterations in a substantial proportion of patients with non‐squamous NSCLC despite previously identified driver alterations, with some findings leading to subsequent matched targeted therapies.
Yoshihiro Masui, Tatsuya Yoshida, Yoh Yamaguchi, Jun Miyakoshi, Ryoko Inaba Higashiyama, Akiko Tateishi, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tomonori Mizutani, Hidehito Horinouchi, Kouya Shiraishi, Takashi Kohno, Takafumi Koyama, Noboru Yamamoto, Yasushi Goto   +15 more
wiley   +1 more source

A Case of Syndrome of Inappropriate Secretion of Antidiuretic Hormone Induced by Selpercatinib in a Patient With RET Fusion Gene‐Positive Non‐Small Cell Lung Cancer

Respirology Case Reports
An 80‐year‐old woman with a lung nodule in the right lower lobe and pleural thickening was diagnosed with lung adenocarcinoma by a surgical lung biopsy.
Yuma Tanaka, Naoya Ikegami, Kodai Miyamoto, Yusuke Shingu, Nobuhiro Okagaki, Hiroto Sakamoto, Tsukasa Nakanishi, Satoshi Nakamura, Kazuki Matsumura, Masakuni Ueyama, Yusuke Kaji, Seishu Hashimoto, Eisaku Tanaka, Yoshio Taguchi, Yuki Ohsumi, Tatsuo Nakagawa, Satoshi Matsunaga, Takashi Hajiro   +17 more
doaj   +1 more source

Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report

JTO Clinical and Research Reports
RET fusion-positive NSCLC accounts for 1% to 2% of lung carcinoma cases. Although two Food and Drug Administration–approved selective RET inhibitors, pralsetinib, and selpercatinib, have revealed efficacy in managing RET fusion-positive NSCLC, this case ...
Illaa Smesseim, MD, Tijmen van der Wel, MD, Sushil K. Badrising, MD, PhD   +2 more
doaj   +1 more source

Patient-Reported Outcomes From LIBRETTO-431: First-Line Selpercatinib Versus Chemotherapy With Pembrolizumab in RET Fusion-Positive NSCLC

JTO Clinical and Research Reports
Introduction: The benefit of first-line selpercatinib versus platinum-based chemotherapy with or without pembrolizumab in patients with advanced RET fusion-positive NSCLC has been previously reported.
Caicun Zhou, MD, PhD, Silvia Novello, MD, PhD, Pilar Garrido, MD, PhD, Christophe Dooms, MD, PhD, Jorge Alatorre-Alexander, MD, Niels Reinmuth, MD, Gill Worthy, PhD, Kim Cocks, PhD, Justin Williams, PhD, Hongmei Han, MS, MApSt, Minji K. Uh, PhD, Nalin Payakachat, PhD, Adrienne M. Gilligan, PhD, Koichi Goto, MD, PhD   +13 more
doaj   +1 more source

RET fusion mutation detected by re-biopsy 7 years after initial cytotoxic chemotherapy: A case report

Frontiers in Oncology, 2022
Personalized medicine using molecular-targeted drugs to achieve better therapeutic response and long-term prognosis is common practice for lung cancer treatment.
Kei Morikawa, Hiroshi Handa, Junko Ueno, Hajime Tsuruoka, Takeo Inoue, Naoki Shimada, Junki Koike, Seiji Nakamura, Yoshiharu Sato, Masamichi Mineshita   +9 more
doaj   +1 more source

Next‐Generation Sequencing‐Based Molecular Profiling and Management of Advanced Solid Tumors: A Real‐World Experience in a Community‐Based Academic Cancer Center

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Advances in molecular and cell biology have led to a paradigm shift in cancer management. We implemented next‐generation sequencing (NGS) at our community‐based academic cancer center over a decade ago. We sought to optimize the use of genomics and understand its impact in identifying actionable genomic alterations to determine ...
Gayathri Moorthy, Annette Sereika, Karen Kaul, Megan Parilla, Mir B. Alikhan, Michael Bouma, Dyson Wake, Peter J. Hulick, Henry M. Dunnenberger, Linda M. Sabatini, Mathew Yang, Kathy A. Mangold, Erin Proctor, Nicholas Evans, Nicholas Miller, Donald L. Helseth Jr, Darryck Maurer, Justin Brueck, Janardan Khandekar, Bruce Brockstein   +19 more
wiley   +1 more source